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ABSTRACT
Benzidine (BZ) and beta-naphthylamine (BNA) have been classified as definite human carcinogens for bladder
cancer by the International Agency for Research on Cancer. However, the epidemiological evidence for an
association between exposure to BZ and/or BNA and lung cancer has been inconclusive. We conducted a systematic
review and meta-analysis to determine the risk for lung cancer among workers exposed to BZ/BNA. A systematic
literature search was conducted to identify studies that had reported occupational BZ/BNA exposure and the outcome
of interest (lung cancer death and/or incidence). Meta-analyses were performed using random effects models to
combine standardized mortality ratios (SMRs) or standardized incidence ratios (SIRs). We identified 23 retrospective
cohort studies including 1745 cases of lung cancer; only one study reported smoking-adjusted lung cancer risk.
A significantly increased lung cancer risk (pooled SMR/SIR 1.28; 95% CI, 1.14–1.43) was observed by combining
all studies, with significant heterogeneity among studies (I2 = 64.1%, P < 0.001). Effect estimates were higher for
studies with direct BZ/BNA exposure (ie, dyestuff and manufacturing industries) (pooled SMR/SIR 1.58; 95% CI,
1.31–1.89), and studies that identified BZ/BNA-associated bladder cancer with SMR/SIR ≥4.7 (pooled SMR/SIR
1.68; 95% CI, 1.35–2.09). Effect estimates were similar for studies with and without concomitant occupational
exposure to chromium, asbestos, arsenic, or bis(chloromethyl) ether. The cumulative meta-analysis showed that
the evidence of association between occupational BZ/BNA exposure and lung cancer has been stable since 1995.
Although the results of this meta-analysis have the potential for confounding by smoking and heterogeneity, our
findings suggest that a finding of lung cancer following occupational BZ/BNA exposure should be considered to be
a potential occupational disease.
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INTRODUCTION
Benzidine (BZ) and beta-naphthylamine (BNA), which are
aromatic amines, are classified by the International Agency for
Research on Cancer (IARC) as definite human carcinogens
(Group 1) on the basis of sufficient evidence of bladder
cancer in animals and human beings.1,2 Because of their
carcinogenicity, the manufacture and use of BZ and BNA
have been prohibited in most advanced countries.3,4 However,
the production and use of BZ and BNA have been reported
in some developing countries,5 occupational exposure to BZ
and/or BNA still occurs in laboratory research and diagnostic
testing,1,2 and some aromatic amines that have been used as
substitutes can metabolize in the body to BZ or BNA.2,6,7
Therefore, occupational exposure to BZ and/or BNA is an
ongoing issue.
In addition to the carcinogenicity of BZ and BNA on the
bladder, some occupational epidemiological studies have
observed carcinogenic risks at sites besides the bladder
(eg, lungs,8–11 esophagus,8 liver, gallbladder, bile duct,12
intestines, larynx,13 and lymphohematopoie14).11 However,
the epidemiological evidence for BZ- and/or BNA-induced
cancers other than in the bladder is not as strong. This is due
to inconsistencies in tumor site studies.11
Some of the studies that examined cancer risk from
occupational exposure to BZ and/or BNA have identified a
significantly increased risk of lung cancer.8–11 However,
most studies8–10 failed to confirm a positive dose-response





relationship between BZ/BNA exposure and the risk for lung
cancer due to an insufficient number of cases. The inadequate
statistical evidence of those individual studies would not allow
for a proper interpretation of the effect of BZ and/or BNA in
regards to lung cancer. Additionally, to our knowledge, there
have been no meta-analyses of lung cancer risk in workers
exposed to BZ and/or BNA.
To examine whether occupational exposure to BZ and/or
BNA is associated with the risk of lung cancer, we conducted
a systematic review and meta-analysis using data from occu-
pational epidemiological studies regarding the association of
BZ and/or BNA with lung cancer risk.
METHODS
This systematic review and meta-analysis was conducted
following the Meta-analysis of Observational Studies in
Epidemiology (MOOSE) guidelines15 and was reported in
accordance with the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) statement.16 This sys-
tematic review protocol was registered with the International
Prospective Register of Systematic Reviews (PROSPERO)
database (registration number: CRD42014010250) and
published in an academic journal.17 This systematic review
and meta-analysis is based on a method of prospective
systematic reviews.18
Participants
We included subjects with unequivocal evidence of
occupational exposure to BZ and/or BNA, such as dyestuff
workers, workers from BZ/BNA manufacturing plants,
leather tannery workers who used BZ-based dyes, and
rubber industry workers exposed to BZ/BNA present as a
contaminant in antioxidants used in manufacturing. Subjects
who worked at the same factories but were not exposed to
either BZ or BNA were excluded.
Study designs
Eligible studies were comparative observational studies that
reported occupational BZ/BNA exposure and the outcome of
interest (lung cancer death and/or lung cancer incidence).
Retrospective cohort studies (also known as historical cohort
studies), prospective cohort studies, and case-control studies
were included in this review.
Exposures
For cohort studies, ascertainment of exposure to BZ and/or
BNAwas based on written records of exposure measurements
or work history. For case-control studies, BZ and/or BNA
exposure was ascertained by secure records (eg, surgical
records), structured interviews with blinding to case/control
status, interviews without blinding to case/control status, or
written self-reports.
Comparators
For cohort studies, use of a comparator was not a requirement
for inclusion. For case-control studies, the control group must
have included subjects who had no history of lung cancer.
Outcomes
Our outcomes were lung cancer death and/or lung cancer
incidence based on clinically confirmed diagnoses (ie, death
certificates, cancer registry or other national recording system,
or hospital or doctor’s records). Effect measures included
standardized mortality ratio (SMR), standardized incidence
ratio (SIR), and odds ratio (OR) for the association between
BZ/BNA exposure and lung cancer risk. SMRs and SIRs were
based on an external comparison group (ie, national or
regional population), and ORs were based on a population-
or hospital-based control group.
Search strategy
The search strategies were carried out by the research team
and an expert librarian (TS). No language restriction was
enforced, conditional to the provision of an English abstract.
A date restriction was not imposed. A comprehensive search
of databases from each database’s earliest inclusive dates to
September 11, 2014, was conducted; a subsequent update
search (to March 19, 2015) was also conducted. The databases
included MEDLINE, Excerpta Medica DataBase (EMBASE),
and Cumulative Index to Nursing and Allied Health Literature
(CINAHL). Search terms included controlled vocabulary and
text-words, and details of the search strategy for MEDLINE
are provided in eTable 1. Additional studies were identified
from the reference list of articles and relevant reviews.
Furthermore, we contacted the authors of the studies we
included, asking them for data about other published or
unpublished works our search had not found.
Study selection
We assessed for inclusion all titles and abstracts identified
during the literature search. Two of the authors (KT and KS)
independently examined the search results for potentially
eligible studies. Disagreements were resolved through
consultation with a third author (KO). For studies that
appeared to meet the criteria for this review, we obtained
and examined the full-text articles. If multiple reports of the
same study were encountered, they were used only once;
the record containing the most data (for example, greatest
sample size, or longest follow-up period) was used. This
usually meant using the most recently published reference,
but if lung cancer risk data was only noted an earlier paper,
that information was used.19 For studies reporting data on
incidence and mortality, incidence data were selected.
Data extraction
Two of the authors (KT and KS) independently extracted
study details from the full text articles using a pilot-tested
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form. When discrepancies arose, a third author (KO)
negotiated a consensus. We abstracted data on the number
of observed deaths or cases, the number of expected deaths
or cases, and the effect measure and the 95% confidence
interval (CI) for lung cancer (essential) and bladder cancer
(if available). We collected data on bladder cancer to assess
heterogeneity between the included studies. For the studies
in which CIs were not reported, we calculated them by the
exact probabilities of the Poisson distribution using the
observed deaths/cases and expected deaths/cases reported
in the articles.20 If a study used both national and regional
populations to compute the expected deaths/cases, the
regional results were used, because a regional population of
study subjects is preferable to the national population for
controlling geographic differences in disease incidence.21 Data
on the following study characteristics were also extracted
where available: year of publication, proportion of males,
duration of follow-up, duration of employment, country and
geographic area, industry type, occupational exposure to
chemicals (including BZ and BNA), information on cigarette
smoking, and information relating to quality assessment. Also,
information concerning national lung cancer incidence rates
were obtained from GLOBOCAN 2012 estimates,22 and data
on national prevalence of cigarette smoking was obtained
from the World Health Organization Report on the Global
Tobacco Epidemic 2013.23
Quality assessment
Quality was assessed by two reviewers (KT and KS), and
discrepancies were resolved by consulting with a third re-
viewer (KO). For case-control studies, we used the Newcastle-
Ottawa Scale (NOS).24 This assessment scale consists of
eight items that are categorized into three major components:
selection, comparability, and exposure. For cohort studies,
a modified version of the NOS19 was used. This modified
NOS was developed for assessing the quality of occupational
cohort studies and includes five quality components: repre-
sentativeness of the exposed cohorts, exposure assessment/
reporting, comparability of exposed and non-exposed cohort,
assessment of outcomes, and adequacy of follow-up.
Data synthesis
We performed meta-analysis to obtain the weighted average
(pooled) of the SMR and SIR for cohort studies and the OR
for case-control studies using the Comprehensive Meta-
Analysis version 2.0 software (Biostat, Englewood, NJ,
USA). Effect measures were pooled using random-effects
models, which were weighted using the inverse of the
variance.25 The presence of between-study heterogeneity
was assessed using the I2 test.26 Publication bias was also
examined visually using funnel plots and mathematically
using the Egger regression asymmetry test.27
In order to explain any heterogeneity seen between studies,
we used subgroup analyses. The covariates considered were
study outcome (incidence vs mortality), study area (Asia
vs Europe vs the United States), reference group (national
vs regional), cohort/sample size, type of industry, type of
exposure to BZ/BNA, occupational exposure to some
carcinogen for lung cancer (no vs yes), year of starting the
production/use of BZ/BNA, follow-up duration, SMR/SIR for
bladder cancer, national incidence rate for lung cancer, and
national prevalence of cigarette smoking. The covariates with
continuous variables were divided into two subgroups using
the median. High SMR/SIR for bladder cancer was used as
the proxy measure for probable higher exposure to BZ/BNA.
Based on the information on type of industry, the situation of
exposure to BZ/BNA was dichotomized into direct (dye and
manufacture) and indirect (leather tanning and rubber).
In our sensitivity analyses, we separately analyzed category
outcomes of the assessed study quality variables to determine
if there was any relationship between quality and outcome.
Additionally, we assessed the influence individual studies had
on the pooled estimate by deleting all risk estimates of each
study from the meta-analysis and determining the range of
pooled estimates. We also conducted a cumulative meta-
analysis in publication year order to determine just when the
risk estimate became statistically significant and to clarify any
variations.28
Instead of a dose-response analysis, we did a meta-analysis
that combined the results of workers who had the highest
occupational BZ/BNA exposure from studies reporting data
relevant to level of exposure to BZ/BNA.29
RESULTS
Description of included studies
Our search identified 460 candidate references (Figure 1).
After the title and abstract assessment, 390 of those articles
were excluded. After full-text assessment, we determined
that 23 studies met the inclusion criteria, and we included
these studies in this analysis.8–14,30–45 We could identify
neither prospective cohort studies nor case-control studies
that examined the association between lung cancer and
occupational exposure to BZ/BNA. Therefore, all the
included studies were retrospective cohort studies. Table 1
summarizes the main characteristics of the cohort studies
investigated in this meta-analysis (the papers are described in
detail in eTable 2, eTable 3, and eTable 4).
The meta-analysis included studies that covered 1745
cases of lung cancer. Cohort studies had been carried out in
Europe, the United States, and Asia from 1976–2015. The
industries investigated included dye production (n = 9),
leather tanning (n = 5), the rubber industry (n = 5), and BZ/
BNA manufacturing (n = 4). Regarding smoking, four of the
included studies reported information on cigarette smoking,
but only one study11 calculated the smoking-adjusted risk
for lung cancer. Regarding gender, most of the study subjects
were male. Nine studies contained only males, and most
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585 records identified through database 
searching
32 additional records identified through 
other sources (search by hand)





23 retrospective cohort 
studies included in this 
systematic review
47 excluded after full-text screening
Reason for exclusion
3 - No study population 
8 - No occupational BZ/BNA exposure 
14 - No outcomes of interest 
1 - Not original
21 - Not latest (i.e. earlier studies)
Figure 1. Flow diagram for selection of studies included in the systematic review.




(first author and year of publication)






1 Fox, 197630 Rubber BNA UK 12781 100 No
2 Delzell, 198231 Rubber BNA USA 2666 100 No
3 Morinaga, 198212 Manufacturing Mixed Japan 244 NA No
4 Gustavsson, 198632 Rubber BNA Sweden 3000c 65 No
5 Costantini, 198933 Tannery BZ Italy 2926 100 No
6 Delzell, 198934 Dye BZ USA 379 100 No
7 Sorahan, 198935 Rubber BNA UK 15206 100 No
8 Chen, 199036 Tannery BZ China 901 100 Yes
9 Morinaga, 199037 Manufacturing Mixed Japan 794 100 No
10 You, 199038 Dye BZ China 550 76.2 Yes
11 Bulbulyan, 19958 Dye Mixed Russia 514 52.6 No
12 Naito, 199539 Dye Mixed Japan 356 98.9 No
13 Sitarek, 199540 Dye BZ Poland 1500c 81.8 No
14 Szeszenia-Dąbrowska, 199541 Rubber Mixedd Poland 6978 100 No
15 Montanaro, 199742 Tannery BZ Italy 1244 69.9 No
16 Axtell, 19989 Dye Mixedd USA 1314 94.9 No
17 Cassidy, 200310 Manufacturing BNA USA 374 93.5 Yese
18 Stern, 200343 Tannery BZ USA 2000c 75.6 No
19 Rosenman, 200414 Dye BZ USA 285 90.7 No
20 Mikoczy, 200544 Tannery BZ Sweden 2027 76.2 No
21 Pira, 201013 Dye Mixed Italy 590 100 No
22 Brown, 201145 Manufacturing BZ USA 847 85 No
23 Tomioka, 201511 Dye Mixed Japan 224 92.2 Yes
AA, aromatic amines; NA, not available.
aThe number of sub-cohorts included in this meta-analysis.
bPercentage of males in the total cohort.
cEstimated due to a lack of data on the number of sub-cohorts.
dMainly BNA.
eIncomplete data.
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cohorts with males and females either excluded females from
the analysis or presented risk estimates for males and females
combined. Regarding the overall meta-analysis, we used the
data for male workers when available. If male data had not
been published for the individual studies, the effect estimates
for both sexes were used in the overall meta-analysis. For
occupational exposure to chemicals other than BZ and
BNA (see eTable 2), some cohorts were potentially exposed
to chromium,46 asbestos,47 arsenic,48 and bis(chloromethyl)
ether,49 which are classified by the IARC as “carcinogenic
to humans” (Group 1) based on evidence of increased lung
cancer in people.
The results of the study quality assessment are shown in
eTable 5. Quality assessment indicated that 1) in representing
the exposed cohort, 20 studies were rated as being high
quality (ie, representative); 2) in regards to exposure, 19
studies had high-quality data (ie, formal exposure records
based on work history derived from company records),
while no studies reported exposure in terms of work-place
measurements; 3) for comparability, 12 studies were rated
high quality (ie, the use of standard adjustment methods),
while nearly half of the included studies (n = 11) did not use
appropriate methods according to the criteria defined in the
modified NOS; 4) as for outcome assessments, 19 studies
were assessed using formal records (ie, cancer registry or
death certificates); and 5) regarding follow-up adequacy, over
half of the studies (n = 12) had nearly complete follow-up
(ie, 5% or less of the cohort remain untraced), while 6 studies
did not report on loss to follow-up.
Results of the overall meta-analysis
A forest plot summarizing the results and weights applied to
each study is shown in Figure 2. The 23 effect estimates from
included studies ranged from 0.49 to 3.73 and resulted in a
significantly increased overall pooled risk estimate of 1.28
(95% CI, 1.14–1.43), with significant heterogeneity among
studies (I2 = 64.1%, P < 0.001).
Subgroup analysis
There was enough heterogeneity evidence that it was decided
to investigate possible explanatory factors. Table 2 presents
the findings from the subgroup analyses for all covariates.
The 8 studies reporting incidence of lung cancer resulted in a

























Overall (I2 = 64.1%, p <0.001)
First author, year Number of lung  Risk
cancer c
estimate  Relative
ases (95% CI) weight (%)
212 (M) 1.05 ( 0.91 -1.21 ) 8.7
59 (M) 0.88 ( 0.68 -1.14 ) 6.7
3 (I) 2.88 ( 0.76 -10.88 ) 0.7
25 (I) 1.24 ( 0.82 -1.88 ) 4.4
29 (M) 1.31 ( 0.91 -1.88 ) 5.0
2 (M) 0.67 ( 0.12 -3.69 ) 0.4
923 (M) 1.36 ( 1.27 -1.45 ) 9.6
16 (I) 0.83 ( 0.49 -1.40 ) 3.3
6 (M) 1.07 ( 0.44 -2.61 ) 1.4
9 (I)* 1.27 ( 0.62 -2.60 ) 2.1
24 (I) 2.28 ( 1.50 -3.46 ) 4.3
3 (M) 0.49 ( 0.13 -1.85 ) 0.7
23 (M) 1.34 ( 0.87 -2.06 ) 4.2
148 (M) 1.22 ( 1.03 -1.44 ) 8.2
29 (M) 1.03 ( 0.70 -1.51 ) 4.7
41 (M) 1.67 ( 1.22 -2.29 ) 5.7
11 (M) 3.73 ( 1.97 -7.07 ) 2.5
44 (M) 0.97 ( 0.71 -1.32 ) 5.8
10 (M) 1.63 ( 0.83 -3.20 ) 2.3
28 (I)† 1.22 ( 0.82 -1.81 ) 4.6
27 (M) 1.27 ( 0.86 -1.88 ) 4.7
55 (I) 1.08 ( 0.82 -1.43 ) 6.3
18 (I) 2.58 ( 1.58 -4.21 ) 3.6
1745 1.28 ( 1.14-1.43 ) 100.0
Figure 2. Forest plot of studies included in the meta-analysis of exposure to benzidine and/or beta-naphthylamine and
lung cancer: all studies combined. I, incidence; M, mortality. *Respiratory cancer. †Obtained by contacting
author.
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with a pooled estimate of 1.23 (95% CI, 1.07–1.42) from the
15 lung cancer mortality studies. The amount of variation
due to heterogeneity (I2) was the same for both subgroups
(I2 = 65.4%). Cohort size, type of industry, situation of
exposure to BZ/BNA, and magnitude of the SMR/SIR for
bladder cancer were each statistically significant predictors
of the pooled risk estimates for lung cancer. Pooled risk
estimates were elevated for dyestuff workers (1.60; 95% CI,















Mortality 1567 15 1.23 (1.07–1.42) 65.4 <0.001
Study area




Europe 1468 10 1.28 (1.09–1.50) 55.0 0.018
United States 222 7 1.25 (1.01–1.56) 76.3 <0.001
Reference group




Regional 124 7 1.48 (1.14–1.92) 73.9 0.001
Cohort size




Small (224–847) 168 11 1.60 (1.29–1.98) 63.9 0.002
Type of industry




Leather tanning 146 5 1.07 (0.85–1.36) 0.0 0.568
Manufacturing 75 4 1.51 (1.07–2.14) 78.1 0.003
Rubber 1367 5 1.15 (0.95–1.38) 79.3 0.001
Situation of exposure to BZ/BNA (Relisted)




Indirect (tannery and rubber) 1513 10 1.12 (0.97–1.29) 64.6 0.003
Type of exposure to BZ/BNA




BZ 245 10 1.13 (0.93–1.37) 0.0 0.784
Mixed 270 8 1.56 (1.25–1.95) 63.3 0.008
(Relisted)
BNA (BNA and mixed) 1500 13 1.40 (1.19–1.65) 76.6 <0.001
BZ (BZ and mixed) 515 18 1.30 (1.13–1.49) 45.7 0.018
Occupational exposure to some carcinogen for lung cancerb




Yes 307 7 1.37 (1.11–1.68) 74.2 0.001
Year of starting the production/use of BZ/BNA




Late (1946–67) 1251 10 1.28 (1.05–1.56) 64.1 0.003
Follow-up duration




Short (6–38 years) 414 12 1.35 (1.12–1.63) 74.9 <0.001
Bladder cancer SMR/SIRc




Low (0.58–2.73) 1609 12 1.15 (1.02–1.31) 63.1 0.002
National incidence rate for lung cancer in 2012d




Low (19.4–38.8) 1303 11 1.27 (1.07–1.52) 57.7 0.009
Prevalence of male smoking in 2011e




Low (21–25) 1410 11 1.24 (1.05–1.46) 73.9 <0.001
Sensitivity analysesf
Representativeness: representative 1703 20 1.24 (1.10–1.39) 61.2 <0.001
Exposure measurement: formal 1666 19 1.24 (1.09–1.42) 63.1 <0.001
Comparability of groups: standard 1345 12 1.35 (1.17–1.55) 61.2 0.003
Assessment of outcome: formal 1681 19 1.28 (1.13–1.46) 69.6 <0.001
Adequacy of follow-up: virtually complete 1340 12 1.26 (1.05–1.50) 72.0 <0.001
aBetween subgroups.
bChrome, asbestos, arsenic, and bis(chloromethyl) ether.
cData not available in the Morinaga (1982) study.
dAge-standardized rates per 100000 men.
eAge-standardized estimated prevalence of smoking among males aged 15 and older.
fPooled risk estimate obtained after excluding all studies but those rated as having the highest grade for each quality component individually.
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1.29–1.99) and workers at BZ/BNA manufacturing plants
(1.51; 95% CI, 1.07–2.14), but not for leather tanning workers
(1.07; 95% CI, 0.85–1.36) or workers in the rubber industry
(1.15; 95% CI, 0.95–1.38). Pooled risk estimates were
increased for small cohorts (1.60; 95% CI, 1.29–1.98)
compared with large cohorts (1.17; 95% CI, 1.02–1.34);
workers with direct exposure to BZ/BNA (1.58; 95% CI,
1.31–1.89) compared with workers with intermittent contact
with BZ/BNA (1.12; 95% CI, 0.97–1.29); and cohorts that
reported an SMR/SIR for bladder cancer ≥4.7 (1.68; 95% CI,
1.35–2.09) compared with other cohorts (1.15; 95% CI,
1.02–1.31). Pooled risk estimates were similar in workers
with occupational exposure to some carcinogens for lung
cancer (1.37; 95% CI, 1.11–1.68) and workers without
occupational exposure to carcinogens for lung cancer (1.24;
95% CI, 1.07–1.44). No difference in risk was found between
cohorts that started the production/use of BZ/BNA before
1945 and cohorts that initiated it after 1945, as well as
between studies with high national incidence rates for lung
cancer and studies with low rates. In addition, no difference in
risk was shown between cohorts with high prevalence of male
smoking and cohorts with low prevalence of male smoking.
In subgroup analyses, all but four subgroups (dyestuff
workers, leather tanning workers, exposure to BZ, and long




Through subgroup analyses, we tried to determine if study
quality influenced outcome. The bottom of Table 2 presents
the results of omitting all studies but those of the highest
quality for each separate quality component. Results remained
robust after exclusion of those studies perceived to be of lower
quality.
Influence of individual studies
Sensitivity analysis by omitting each study in turn had no
effect on the meta-analysis results and showed robust results
(see eFigure 1). The pooled risk estimate ranged from 1.24
to 1.31, and all pooled risk estimates were statistically
significant.
Assessing publication bias
Visual examination of the funnel plot (see eFigure 2) used to
determine publication bias revealed no systematic relation
between study size and magnitude of the estimator (SMR/
SIR). Likewise, the Egger test did not show significant funnel
plot asymmetry (intercept, −0.02; 95% CI, −1.09 to 1.05;
one-tailed P-value = 0.48).
Cumulative meta-analysis
The results of the cumulative meta-analysis are depicted
























First author, year   Pooled risk estimate 
(95% CI)


























1.05 ( 0.91 - 1.21 )
1.00 ( 0.85 - 1.17 )
1.01 ( 0.80 - 1.27 )
1.04 ( 0.86 - 1.25 )
1.08 ( 0.91 - 1.28 )
1.07 ( 0.92 - 1.25 )
1.16 ( 0.97 - 1.40 )
1.13 ( 0.95 - 1.35 )
1.13 ( 0.95 - 1.34 )
1.14 ( 0.97 - 1.34 )
1.21 ( 1.02 - 1.44 )
1.20 ( 1.01 - 1.42 )
1.21 ( 1.03 - 1.42 )
1.21 ( 1.05 - 1.38 )
1.19 ( 1.05 - 1.36 )
1.23 ( 1.08 - 1.39 )
1.28 ( 1.11 - 1.46 )
1.25 ( 1.10 - 1.43 )
1.26 ( 1.11 - 1.43 )
1.26 ( 1.11 - 1.42 )
1.25 ( 1.12 - 1.41 )
1.24 ( 1.11 - 1.39 )
1.28 ( 1.14 - 1.43 )
Figure 3. Forest plot of cumulative meta-analysis of lung cancer and occupational exposure to benzidine and/or beta-
naphthylamine. Pooled risk estimates (with 95% confidence intervals) by year of publication of subsequent
reports. Vertical solid lines = no effect.
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1.02–1.44) in 1995, when the first 10 cohort studies had been
published. Although 12 additional cohort studies have been
published since, the summary estimates have stayed basically
steady, and these results have remained significant until the
end of the analysis.
Analysis of highly exposed groups
We identified 6 studies that evaluated the risk estimates of
exposure levels among BZ/BNA-exposed workers (see
eTable 6). The pooled lung cancer risk estimate, based on
these six high-exposure groups, was 2.33 (95% CI, 1.31–
4.14). We found significant heterogeneity across all studies
(I2 = 67.2%, P = 0.009).
DISCUSSION
We conducted a systematic review and meta-analysis to
investigate the association between occupational BZ/BNA
exposure and risk of lung cancer. A total of 23 retrospective
cohort studies of 1745 cases were included in the analysis. We
found a significantly increased risk of lung cancer among
workers exposed to BZ/BNA occupationally, with an overall
pooled risk estimate of 1.28 (95% CI, 1.14–1.43). Results
from cumulative meta-analysis and sensitivity analysis and an
absence of publication bias suggest that the results are reliable
and robust.
A major finding here is that the pooled risk estimate for
lung cancer was elevated both in those studies in which
BZ/BNA-associated bladder cancer relative risks were also
elevated (pooled risk estimate 1.68; 95% CI, 1.35–2.09) and
in those studies in which workers had many opportunities for
direct exposure to BZ/BNA (pooled risk estimate 1.58; 95%
CI, 1.31–1.89). The results from this analysis of highly
exposed workers also indicate a stronger effect than among all
workers combined (pooled risk estimate 2.33; 95% CI, 1.31–
4.14). In this meta-analysis, no studies reported exposure as
work-place measurements, which are the most accurate and
unbiased occupational exposure estimates. However, since
BZ/BNA exposures are generally apt to be higher in studies
finding elevated bladder cancer rates, the presence of a
positive bladder cancer finding may be a legitimate substitute
for high BZ/BNA exposure. In meta-analysis of cancer risk in
occupational settings, a similar approach has been adopted
for the purpose of identifying a highly exposed subgroup.29,50
For example, in a meta-analysis of occupational exposure to
asbestos and ovarian cancer, the SMR for lung cancer was
employed.29 Additionally, workers with direct exposure to
BZ/BNA (eg, dyestuff workers and workers at BZ/BNA
manufacturing plants) are likely to have been exposed to
higher concentrations of BZ/BNA than workers exposed to
BZ/BNA indirectly (eg, leather tannery workers and rubber
industry workers). Hence, these results provide more evidence
that the positive findings in this meta-analysis are due to BZ/
BNA exposure. Nevertheless, in addition to higher BZ/BNA
exposure, reporting a high risk (risk estimate ≥4.7) of bladder
cancer may indicate greater confounding by smoking.
Therefore, the possibility of a confounding effect from
smoking in the studies identifying increased risks of bladder
cancer should be considered.
It is not known just how BZ and BNA cause lung cancer,
but there is data for a number of possible mechanisms. As
with many other aromatic amines, BZ and BNA must be
metabolized into reactive electrophiles that react with DNA
so they can become carcinogenic.51 While some research has
found variances in the metabolic patterns of monoarylamines,
such as BNA, and diarylamines, such as BZ,52 the main
chemical reactions needed in BZ and BNA metabolism are
the same; initial activation occurs in the liver, and further
metabolism that creates more reactive compounds occurs in
the bladder.51,53 This is why bladder cancer is the main effect
associated with BZ/BNA exposure. The initial activation of
aromatic amines via N-oxidation is mediated primarily by
cytochrome P4501A2 (CYP1A2).53 A prior study did not
detect CYP1A2 in most human extrahepatic tissue.54 Further
metabolism of aromatic amines involves O-acetylation, which
is regulated by the enzymes N-acetyltransferases 1 (NAT1).55
NAT1 are detected not only in the human urinary bladder56 but
also in the human peripheral lung.57 Although aromatic amine
N-oxidation does not take place in the lung, these compounds
could undergo N-oxidation in the liver due to CYP1A2, to
later circulate to the lung, where they could be O-acetylated
by NAT1 found in lung tissue.58 This metabolic activation
pathway is supported by prior studies for 4-aminobiphenyl
(ABP), which is a prototypical aromatic amine; ABP DNA
adducts were detected in human lung tissues obtained by
surgery or autopsy,59 as well as in human urinary bladder
tissue biopsy samples and exfoliated urothelial cells.60,61 With
regard to experimental animals, several studies indicate that
exposure to BZ/BNA can increase the incidence of lung
cancer; indeed, oral administration of BZ produced a high
incidence of lung tumors in mice,62 intraperitoneal injection of
BNA increased the incidence of lung adenomas in mice,63 and
gavage administration of BNA caused lung tumor multiplicity
in mice.64 The capacity of the human lung to metabolically
activate BZ and BNA,57 the presence of DNA adducts of an
aromatic amine in human lung tissues,59 and the experimental
evidence of lung cancer for BZ and BNA in mice62–64 provide
biological plausibility for the findings of this meta-analysis.
A major concern in interpreting our analysis was its
inability to account for smoking, which is an important
non-occupational risk factor for lung cancer.65 Although four
studies obtained information on cigarette smoking, two of
them calculated smoking-adjusted risk only for bladder
cancer,36,38 and one of them had incomplete tobacco
smoking data (lacking in about one third of cohort
members).10 Only one study11 presented an effect estimate
for lung cancer risk from a multivariate model; the relative
risk for lung cancer incidence after adjustment for age at
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first exposure, smoking status, and other occupational co-
exposure was 3.02 (95% CI, 0.84–10.93) for long duration of
employment compared with the short duration group. Lack of
adjustment for smoking might lead to overestimation of the
association between lung cancer and exposure to BZ/BNA.
Therefore, further studies with sufficient data on smoking are
required for a better understanding of the risk for lung cancer
in relation to occupational exposure to BZ/BNA.
A further limitation of our findings is the issue of
heterogeneity between studies. Statistically significant
heterogeneity was noted not only in the meta-analysis of all
studies combined but also in subgroup analysis and sensitivity
analysis. Heterogeneity is due to methodological diversity
between the studies and shows up in the observed effects,
being even far more different from each other than one would
expect randomly.66 In observational epidemiology, study
designs, populations, exposure assessing and outcome
methods, and statistical analyses are rarely, if ever, the
same.50 Therefore, meta-analysis of observational studies has
the potential to introduce bias and confounding.15 Although we
conducted subgroup analysis to explore sources of
heterogeneity, study characteristics and study quality had
little influence on our heterogeneity. A prior review based
on 60 meta-analyses in occupational epidemiology pointed out
that the most obvious finding was the various exposure
definitions these studies employed and the lack of exposure
data, which make comparisons onerous.67 The studies included
in this meta-analysis also used a variety of BZ/BNA exposure
surrogates, such as occupational groups, years of employment,
and duration of employment. The differences in definitions of
BZ/BNA exposure across studies might explain some of the
heterogeneity between studies.
We are aware that occupational cohorts included in this
study not only had simple exposures to BZ/BNA but had
exposures to other chemicals as well. Although we conducted
subgroup analyses and confirmed no difference in the lung
cancer risk between workers with and without occupational
exposure to known lung carcinogens, concomitant occu-
pational exposures to other chemicals was not taken into
consideration. Therefore, the results of this meta-analysis
might be biased due to exposure to other chemicals.
Even though we systematically searched for all published
cohort and case-control studies indexed in MEDLINE,
EMBASE, and CINAHL, none of the identified studies were
case-control studies. In general, case-control studies are supe-
rior to retrospective cohort studies regarding adequate control
of confounding factors, including smoking.68 However, a main
drawback of case-control studies is that exposure information
is obtained by self-reporting after disease has occurred.68
Differential misclassification of exposure due to recall bias
is likely, tending toward overestimation of the association
between exposure and outcome. Therefore, including no case-
control studies might prevent overestimation of the risk for
lung cancer among workers exposed to BZ/BNA.
Despite these limitations, this study has the following
strengths: 1) this is the first meta-analyses of lung cancer risk
in workers exposed to BZ/BNA conducted according to the
method of prospective meta-analysis, which means a meta-
analysis of studies that were identified, evaluated, and
determined to be eligible for the meta-analysis before the
results of any of those studies became known18; 2) the total
number of lung cancer deaths or incident cases was 1745 from
all the cohort studies, providing summarized epidemiological
evidence with adequate statistical power to examine the
association between BZ/BNA exposure and lung cancer;
and 3) our meta-analysis, restricted to workers with probable
higher exposure, is reasonably consistent with an underlying
dose-response effect.
In conclusion, this systematic review and meta-analysis
suggests that occupational BZ/BNA exposure is associated
with an increased risk of lung cancer. One important finding
of this study is that pooled risk estimates were raised in
the subgroup of studies in which workers were probably
exposed to a high level of BZ/BNA. Although confounding
by smoking cannot be completely ruled out, and the
heterogeneity among studies requires cautious interpretation,
our findings suggest that a lung cancer diagnosis following
occupational BZ/BNA exposure may need to be considered a
potential occupational disease.
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